Akebia Therapeutics, Inc. AKBA

0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more TTM periods

225.07 236.20 232.40 219.06
Gross Profit 177.78 196.73 188.28 174.43
Operating Income 17.75 23.50 5.29 (15.13)
EBT (15.29) (3.72) (18.76) (27.85)
Income after Tax (15.90) (5.34) (20.51) (29.67)
Net Income Common (15.90) (5.34) (20.51) (29.67)
Gross Margin 78.99% 83.29% 81.01% 79.63%
EBIT Margin 7.88% 9.95% 2.28% (6.90%)
Net Profit Margin (7.07%) (2.26%) (8.83%) (13.54%)
Free Cash Flow Margin 14.37% 28.74% 25.83% 18.38%
EBITDA 28.04 24.77 6.57 (13.57)
EBIT 17.75 23.50 5.29 (15.13)

Show all line items

In millions of $ except per-share values · columns are period end dates